Implementation of guideline-recommended organ-protective therapy in people with type 2 diabetes and cardiovascular disease, heart failure, or kidney disease: real-world evidence from a German University Hospital

Guideline recommendations for organ protection in PwT2D and cardiorenal comorbidities are increasingly reflected in clinical practice, yet a substantial care gap persists, with the majority of individuals remaining untreated. Certain subpopulations - particularly women - are underrepresented among those receiving guideline adherent therapy. Further research into the causes of undertreatment and development of targeted implementation strategies is needed to close remaining evidence-practice gaps.